Pilot Randomized Neo-adjuvant Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2017
At a glance
- Drugs IMA 950 (Primary) ; Poly ICLC (Primary) ; Varlilumab (Primary)
- Indications Astrocytoma; Oligodendroglioma
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 20 Jan 2017 Planned End Date changed from 1 Oct 2018 to 1 Jan 2019.
- 20 Jan 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2018.